Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Dif

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types is a phase 2/3, interventional study registered as NCT06782412 by KU Leuven, with a registry enrolment figure of 109 participants, started 2025-02-06 and due to reach its primary completion in 2027-12. Interventions recorded: [18F]AlF-FAPI-74 PET/CT. Conditions listed: Oesophageal Cancer; Gastric Cancer; Pancreatic Ductal Adenocarcinoma; FAP; Oncology; Oncologic Disorders. Primary outcome: Primary Objective OGA: demonstrate superiority of [18F]AlF-FAPI-74 PET/CT over [18F]FDG PET/CT.; Primary Objective PDAC: demonstrate superiority of [18F]AlF-FAPI-74 PET/CT over conventional imaging (CT or MRI) or [18F]FDG PET/CT (if available); Primary Objective Clinically Challenging Situation: dem. Pancreatic eligibility wording from the registry: "New histologic or cytologic proven diagnosis of pancreatic ductal adenocarcinoma". Sites: Belgium. No results are recorded here; the registry entry is the source.